FDA: No advisory meeting needed for Corcept drug

Corcept Therapeutics Inc.’s route to approval for its drug to treat Cushing’s Syndrome just got a little easier.
The Food and Drug Administration told the Menlo Park company (NASDAQ: CORT) that there will be no advisory committee meeting to review Corcept’s new drug application for Corlux, or mifepristone. That eliminates one step of the process toward winning FDA approval, though it does not change the Feb. 17 date that the agency must make a decision about Corlux.